[Potential use of indenolol in hypertensive patients with chronic bronchial asthma].
The data are reported on a double blind clinical experiment using indenolol on a group of asthmatic hypertensives. The drug revealed a satisfactory anti-hypertensive action in the absence of any significantly bronchoconstrictive effect. The orciprenaline test performed at the end of the experiment showed that the drug does not reduce the availability of beta 2 bronchial receptors vis-à-vis the beta 2 stimulants.
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001249:Asthma / Q000503:physiopathology*; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007192:Indenes / Q000627:therapeutic use*; D008297:Male; D009921:Metaproterenol; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D007192:Indenes; D011412:Propanolamines; D009921:Metaproterenol; C002989:indenolol
Possibilità di impiego dell'indenololo negli ipertesi affetti da asma bronchiale cronica.